Democratizing hedge fund level analysis tools for everyone
| Name | Indofarma Tbk. |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Health Care Research |
| Code | F2 |
| Latest Quarterly | 06-30-25 |
| Name | Latest % | A Month Ago % |
|---|---|---|
| PT. Bio Farma (Persero) | 80.66 | 80.66 |
| PT. Asabri (Persero) - Dapen Tni | 13.74 | 13.74 |
| Public < 5% | 5.6 | 5.6 |
| Andi Prazos | 0.0 | 0.0 |
| Didi Agus Mintadi | 0.0 | 0.0 |
| Treasury Shares | 0.0 | 0.0 |
| Sahat Sihombing | 0.0 | 0.0 |
| Source | 2022 | 2021 |
|---|---|---|
| 1682 | INAF | F2 |
| 1683 | INAF | F2 |
| 1684 | INAF | F2 |
| 1685 | INAF | F2 |
| Region | 2022 | 2021 |
|---|---|---|
| 1009 | INAF | F2 |
| 1010 | INAF | F2 |
| Valuation | Ratio | Rank |
|---|---|---|
| P/S | 2.47 | # 14 / 15 |
| EV_EBITDA | -47.87 | --- / 15 |
| PER | -5.89 | --- / 15 |
| PBV | -0.52 | --- / 15 |
| DER | -0.25 | --- / 15 |
| Profitability | Ratio | Rank |
|---|---|---|
| NPM % | -41.9128344613828 | --- / 15 |
| ROA % | -12.97 | --- / 15 |
| ROE % | 8.76 | # 10 / 15 |
| Year | DPS | Yield [%] |
|---|---|---|
| 2026 | 0.0 | 0.0 |
| 2025 | 0.0 | 0.0 |
| 2024 | 0.0 | 0.0 |
| 2023 | 0.0 | 0.0 |
| 2022 | 0.0 | 0.0 |
| 2021 | 0.0 | 0.0 |
| 2020 | 0.0 | 0.0 |
| 2019 | 0.0 | 0.0 |
| Timeframe | Performance |
|---|---|
| 1W % | -3.1 |
| 1Mo % | -45.2 |
| 3Mo % | -68.8 |
| 1Yr % | -79.7 |
| Stocks | PER | Market Cap | EV | Revenue | EBITDA | Net Profit |
|---|---|---|---|---|---|---|
| KLBF | 9.63 | 36.98 T | 32.98 T | 38,958 B | 5,365 B | 3,839 B |
| SOHO | 20.50 | 15.29 T | 14.58 T | 10,725 B | 980 B | 746 B |
| TSPC | 8.24 | 12.76 T | 8.61 T | 14,220 B | 1,885 B | 1,550 B |
| SIDO | 16.01 | 10.68 T | 10.21 T | 2,933 B | 959 B | 667 B |
| MDLA | 6.59 | 2.91 T | 2.75 T | 16,342 B | 643 B | 442 B |
| KAEF | 123.99 | 2.56 T | 8.59 T | 9,403 B | 627 B | 21 B |